Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV004577668 | SCV005061644 | likely pathogenic | Hereditary factor IX deficiency disease | 2024-05-09 | reviewed by expert panel | curation | The c.1325G>C (NM_000133.4) variant in F9 is a missense variant predicted to cause substitution of Glycine by Alanine at amino acid 442 (p.Gly442Ala). This variant has been reported in at least 4 probands meeting the hemophilia B phenotype criteria specified by the Coagulation Factor Deficiency VCEP (PS4_Moderate; PMID: 7937052, poster https://www.postersessiononline.eu/173580348_eu/congresos/WFH2018/aula/-M-P_49_WFH2018.pdf, internal laboratory data). This variant is absent from gnomAD v2.1.1 and v3.1.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.884, which is above the threshold of 0.6, evidence that correlates with impact to F9 function (PP3). Another missense variant c.1234G>A, p.Gly442Arg in the same codon has been classified as pathogenic for hemophilia B by the ClinGen Coagulation Factor Deficiency VCEP (PM5). In summary, this variant meets the criteria to be classified as Likely Pathogenic for X-linked recessive hemophilia B based on the ACMG/AMP criteria applied, as specified by the ClinGen Coagulation Factor Deficiency VCEP: PS4, PM5, PP3, PM2_Supporting. (ClinGen Coagulation Factor Deficiency Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for F9 Version 1.0.0., Released 10/5/2023) |